Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 357

recruiting
3 968
countries
28
conditions
2 103

10 282 trials match your criteria

Anorexia nervosa

Not yet recruiting

Dry extract from Psilocybe cubensis (15‑25:1) with methanol for adults with treatment‑resistant anorexia nervosa: a randomized, active‑placebo, triple‑blind trial

InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years
  • Substances:Dry Extract From Psilocybe Cubensis (15-25:1), Extraction Solvent: Methanol

Epilepsy

Not yet recruiting

Long‑Term Safety and Tolerability of Probenecid (PTI5803) as Adjunctive Therapy in Patients ≥14 Years with Drug‑Resistant Focal Epilepsy due to Focal Cortical Dysplasia

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years

Bipolar disorder

Not yet recruiting

Effect of Adjunctive Pramipexole on Anhedonia in Adults with Bipolar Depression – Randomized, Double‑Blind, Placebo‑Controlled Phase III Trial

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Pramipexole

Acne

Not yet recruiting

Safety and Efficacy Study of the Acne mRNA vaccine (mrt1800, mrt1801, mrt1802) in Adults 18‑45 Years with Moderate to Severe Acne

Investigational
Countries:GermanyGermany
  • Participants:18–64 years

Follicular lymphoma

Not yet recruiting

Study of AZD0486 plus rituximab versus standard chemotherapy drug combination in previously untreated follicular lymphoma patients

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide

Malignant melanoma stage IV+1

Not yet recruiting

Phase Ib/II study of momelotinib with nivolumab or pembrolizumab in unresectable stage III/IV cutaneous melanoma

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab

Neuromyelitis optica spectrum disorder+1

Not yet recruiting

Two dosing schedules of the herpes zoster vaccine (recombinant varicella zoster virus glycoprotein E) in MS and NMOSD patients on rituximab or ocrelizumab

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Ocrelizumab

Systemic scleroderma

Not yet recruiting

Safety and efficacy of obinutuzumab in patients with active diffuse systemic sclerosis: a randomized, double-blind, placebo-controlled trial

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab

Cardiac amyloidosis

Not yet recruiting

Serum Transthyretin Levels in Patients with Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis and Acoramidis: A Within‑Patient Pilot Crossover Study

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Acoramidis

Chronic coronary syndrome

Not yet recruiting

Short Dual Antiplatelet Therapy with Ticagrelor, Aspirin and Clopidogrel vs Standard Therapy in Chronic Coronary Syndrome Patients Undergoing PCI

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid

Acute myeloid leukaemia+1

Not yet recruiting

Safety and feasibility study of CARCIK‑CD123/33 cell therapy in adult and pediatric patients with relapsed or refractory AML and BPDCN

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years

Barth syndrome

Not yet recruiting

Efficacy and Safety of Daily Subcutaneous Elamipretide Trihydrochloride Injections in Patients with Barth Syndrome (Phase 3b/4 Randomized Trial)

Investigational
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Elamipretide Trihydrochloride

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.